Today NICE published their Advice on “AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas”. This formal external review and publication is a significant step in getting AMBLor® adopted into clinical care pathways in the UK. It follows on from...
AMLo Biosciences Ltd (AMLo), an innovative medical device company spun out of Newcastle University specialising in the early detection of skin cancers, is pleased to announce it has secured significant further investment totalling £2.45m. At present all early stage...
A ground-breaking explanation of the mechanism by which early-stage melanomas become at risk of spreading has just been published in the British Journal of Dermatology[1]. The team at Newcastle University, led by Professor Penny Lovat, in association with AMLo...
Increasing evidence for the application of FAK inhibitors in melanoma therapy Presented at the Society for Melanoma Research (SMR) Virtual Congress, October 2021 AMLo’s Chief Scientific Officer, Professor Penny Lovat, participated in the research that is presented in...
Melanoma secretion of TGFβ2 induces loss of epidermal AMBRA1 threatening epidermal integrity and facilitating tumour ulceration Presented at the Society for Melanoma Research (SMR) Congress 2021 by Dr Jane Armstrong, of Newcastle University. Dr Armstrong in Professor...
Artificial Intelligence for risk classification of AMBLor in the melanoma microenvironment Presented at the Society for Melanoma Research (SMR) Congress 2021 by Tom Andrew MBChB, MSC, of Newcastle University AMBLor® will fit very well into pathology workflows as it is...
AMLo Biosciences Limited is a company registered in England and Wales. Company # 11004534
Trading address: Office 9, The Biosphere, Drayman's Way, Newcastle Helix, Newcastle upon Tyne, NE4 5BX
Registered address: c/o RMT Accountants & Business Advisors Ltd, Gosforth Park Avenue, Newcastle upon Tyne, NE12 8EG, United Kingdom
VAT # 285288950
Sign up for our newsletter